New cytotoxic salinosporamides from the marine actinomycete Salinispora tropica

Journal of Organic Chemistry

Volumn 70, Issue 16, 2005, Pages 6196-6203

  Williams, Philip G ^a   Buchanan, Greg O ^a   Feling, Robert H ^a   Kauffman, Christopher A ^a   Jensen, Paul R ^a   Fenical, William ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLATION; ENZYME INHIBITION; METABOLITES; NITROGEN COMPOUNDS;

CHLOROETHYL MOIETY; PROTEASOME; PYRROLE; SALINOSPORAMIDES;

TOXICITY;

GAMMA LACTAM DERIVATIVE; LACTACYSTIN BETA LACTONE; PROTEASOME INHIBITOR; PYRROLE DERIVATIVE; SALINOSPORAMIDE A; SALINOSPORAMIDE B; SALINOSPORAMIDE C; UNCLASSIFIED DRUG;

ACTINOBACTERIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON CARCINOMA; CYTOTOXICITY; DRUG ISOLATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; NONHUMAN; SALINISPORA TROPICA; STRUCTURE ACTIVITY RELATION;

CELL LINE, TUMOR; HUMANS; LACTAMS; MAGNETIC RESONANCE SPECTROSCOPY; MICROMONOSPORACEAE; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 23044479278     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo050511+     Document Type: Article

References (55)

1. Berdy, J. J. Antibiot. 2005, 58, 1-26.
2. Bull, A. T.; Ward, A. C.; Goodfellow, M. Microbiol. Mol. Bol. Rev. 2000, 64, 573-604.
3. Okami, Y.; Hotta, K. In Actinomycetes in Biotechnology; Goodfellow, M., Williams, S. T., Mordarski, M.; Academic Press: New York, 1988; pp 33-67.
4. (a) Jensen, P. R.; Gontang, E.; Mafnas, C.; Mincer, T. J.; Fenical, W. Environ. Microbiol. 2005, 7, 1039-1048.
5. (b) Maldonado, L. A.; Stach, J. E. M.; Pathom-aree, W.; Ward, A. C.; Bull, A. T.; Goodfellow, M. Antonie van Leeuwenhoek 2005, 87, 11-18.
6. (c) Montalvo, N. F.; Mohamed, N. M.; Enticknap, J. J.; Hill, R. T. Antonie van Leeuwenhoek 2005, 87, 27-36.
7. Jensen, P. R.; Dwight, R.; Fenical, W. Appl. Environ. Microbiol. 1991, 57, 1102-1108.
8. Mincer, T. J.; Jensen, P. R.; Kauffman, C. A.; Fenical, W. Appl. Environ. Microbiol. 2002, 68, 5005-5011.
9. Maldonado, L. A.; Fenical, W.; Jensen, P. R.; Kauffman, C. A.; Mincer, T. J.; Ward, A. C.; Bull, A. T.; Goodfellow, M. Int. J. Syst. Evol. Micr., published on-line April 15, 2005.
10. Feling, R. H.; Buchanan, G. O.; Mincer, T. J.; Kauffman, C. A.; Jensen, P. R.; Fenical, W. Angew. Chem., Int. Ed. 2003, 42, 355-357.
11. Recently, compounds analogous to 1 that lacked the chlorine substituent were reported from a terrestrial actinomycete of the genus Streptomyces. Stadler, M.; Seip, S.; Mueller, H.; Mayer-Bartschmid, A.; Bruening, M.-A.; Benet-Buchholz, J.; Togame, H.; Dodo, R.; Reinemer, P.; Bacon, K.; Fuchikami, K.; Matsukawa, S.; Urbahns, K. U.S. Patent 2004071382, 2004.
12. (a) Dick, L. R.; Cruikshank, A. A.; Grenier, L.; Melandri, F. D.; Nunes, S. L.; Stein, R. L. J. Biol. Chem. 1996, 271, 7273-7276.
13. (b) Corey, E. J.; Li, W.-D. Z. Chem. Pharm. Bull. 1999, 47, 1-10 and references therein.
14. Omura, S.; Fujimoto, T.; Otoguro, K.; Matsuzaki, K.; Moriguchi, R.; Tanaka, H.; Sasaki, Y. J. Antibiot. 1991, 44, 113-116 and references therein.
15. Adams, J. Proteasome Inhibitors in Cancer Therapy. Humana Press: Totowa, New Jersey, 2004.
16. Wang, C. Y.; Mayo, M. W.; Korneluk, R. G.; Goeddel, D. V.; Baldwin, A. S., Jr. Science 1998, 281, 1680-1683.
17. Richardson, P. G.; Barogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. N. Engl. J. Med. 2003, 348, 2609-2617.
18. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Mitsiades, C.; Ovaa, H.; Berkers, C.; Munshi, N.; Chao, T.; Nicholson, B.; Neuteboom, S. T.; Richardson, P.; Palladino, M.; Anderson, K. C. Cancer Cell, submitted.
19. (a) Reddy, L. R.; Saravanan, P.; Corey, E. J. J. Am. Chem. Soc. 2004, 126, 6230-6231.
20. (b) Endo, A.; Danishefsky, S. J. J. Am. Chem. Soc. 2005, 127, 8298-8299.
21. (c) Reddy, L. R.; Fournier, J.-F.; Reddy, B. V. S.; Corey, E. J. Org. Lett. 2005, 7, 2699-2701.
22. (a) Crane, S. N.; Corey, E. J. Org. Lett. 2001, 3, 1395-1397.
23. (b) Corey, E. J.; Reichard, G. A.; Kania, R. Tetrahedron Lett. 1993, 34, 6977-80.
24. (c) Nagamitsu, T.; Sunazuka, T.; Tanaka, H.; Omura, S.; Sprengeler, P. A.; Smith, A. B., III J. Am. Chem. Soc. 1996, 118, 3584-90.
25. (d) Corey, E. J.; Li, W.; Reichard, G. A. J. Am. Chem. Soc. 1998, 120, 2230-2236.
26. (e) Corey, E. J.; Li, W.; Nagamitsu, T. Angew. Chem., Int. Ed. 1998, 37, 1676-1679.
27. (f) Corey, E. J.; Li, W. Tetrahedron Lett. 1998,39, 8043-8046.
28. (g) Corey, E. J.; Li, W. Chem. Pharm. Bull. 1999, 47, 1-10.
29. (h) Panek, J. S.; Masse, C. E. Angew. Chem., Int. Ed. 1999, 38, 1093-1095.
30. (i) Soucy, F.; Grenier, L.; Behnke, M. L.; Destree, A. T.; McCormack, T. A.; Adams, J.; Plamondon, L. J. Am. Chem. Soc. 1999, 121, 9967-9976.
31. (j) Crane, S. N.; Corey, E. J. J. Org. Chem. 2003, 68, 2760-2764.
32. (k) Brennan, C. J.; Pattenden, G.; Rescourio, G. Tetrahedron Lett. 2003, 44, 8757-8760.
33. (l) Ooi, H.; Ishibashi, N.; Iwabuchi, Y.; Ishihara, J.; Hatakeyama, S. J. Org. Chem. 2004, 69, 7765-7768.
34. (m) Corey, E. J.; Li, W. Tetrahedron Lett. 1998, 39, 7475-7478.
35. (n) Reddy, L. R.; Saravanan, P.; Fournier, J.-F.; Reddy, B. V. S.; Corey, E. J. Org. Lett. 2005, 7, 2703-2705.
36. Jacque, J.; Gros, C.; Mourcier, S. Absolute Configurations of 6000 Selected Compounds with One Asymmetric Carbon Atom; Georg Thieme Publishers: Stuttgart, Germany, 1997. Specifically, see references for data on 1-chloro-4-methylhex-1-en-3-one, 1-chloro-4-methylhexane, 1-chloro-5- methylheptane, 1-bromo-3-methylnonane, 1-bromo-4-methylnonane, and the corresponding deshalogenated compounds.
37. 4 reduction in i-PrOH and also in DMSO. An attempt was also made to convert 1 to the iodo derivative using the Finkelstein reaction (NaI in refluxing acetone), which under these conditions was not successful.
38. 8 where the structure was originally disclosed. During the review process on this manuscript, it was brought to our attention that the original figure was in violation of the IUPAC rules because a hashed line between two adjacent stereocenters (C-4 and C-5) is not allowed under this system. The stereochemical representations used in this paper for 1-9 are in accord with these IUPAC recommendations. See: Moss, G. P. Pure Appl. Chem. 1996, 68, 2193-2222.
39. Casiraghi, G.; Spanu, P.; Rassu, G.; Pinna, L.; Ulgheri, F. J. Org. Chem. 1994, 59, 2906-2909.
40. Schiehser, G. A.; White, J. D. Tetrahedron Lett. 1986, 46, 5587-5590.
41. (a) Lowe, C.; Vederas, J. C. Org. Prep. Proced. Int. 1995, 27, 305-346.
42. (b) Pommier, A.; Pons, J. M. Synthesis 1993, 5, 441-459.
43. Attempts to determine the absolute configuration of C-5 in 8 and 9 by preparation of the MTPA derivatives resulted in elimination to form 7.
44. For an example of decarboxylation of a β-amide ester under basic conditions, see: Shehata, I. A.; Glennon, R. A. J. Heterocycl. Chem. 1987, 24, 1291-1295.
45. Molecular modeling of the four potential diastereomers (4R,5R,6S; 4R,5S,6S; 4S,4R,6S; 4R,5R,6S) indicates that the lowest energy conformers of these diastereomers are all within 2 kcal/mol. This suggests that all four diastereomers should be produced, albeit in unequal amounts.
46. Pas, M. M.; Das, A.; Palom, Y.; He, Q. Y.; Tomasz, M. J. Med. Chem. 2001, 44, 2834-2842.
47. (a) Fenteany, G.; Standaert, R. F.; Lane, W. S.; Choi, S.; Corey, E. J.; Schreiber, S. L. Science 1995, 268, 726-731.
48. (b) Corey, E. J.; Li, W.-D. Z. Chem. Pharm. Bull. 1999, 47, 1-10.
49. (c) Masse, C. E.; Morgan, A. J.; Adams, J.; Panek, J. S. Eur. J. Org. Chem. 2000, 14, 2513-2528.
50. Boyd, M. R.; Paull, K. D. Drug. Dev. Res. 1995, 34, 91-109.
51. Concentration that limited the growth of a cell line to 50% of the untreated control growth.
52. Concentration that killed 50% of the treated cell line as compared to the untreated cells.
53. For the results of this study, see: Macherla, V. R.; Mitchell, S. S.; Manam, R. R.; Reed, K. A.; Chao, T.-H.; Nicholson, B.; Deyanat-Yazdi, G.; Mai, B.; Jensen, P. R.; Fenical, W.; Neuteboom, S. T. C.; Lam, K. S.; Palladino, M. A.; Potts, B. C. M. J. Med. Chem. 2005, 48, 3684-3687.
54. Recent results suggest that this might indeed be the case. Reddy, L. R.; Fournier, J.-F.; Reddy, B. V. S.; Corey, E. J. J. Am. Chem. Soc. 2005, 7, 2699-2701
55. Upper limit on the antibacterial, antifungal, and antiviral assays is 250, 500, and 20 μg/mL, respectively.